How Might Endotyping Guide Chronic Obstructive Pulmonary Disease Treatment? Current Understanding, Knowledge Gaps and Future Research Needs

Overview

Journal Curr Opin Pulm Med

Specialty Pulmonary Medicine

Date 2021 Jan 4

PMID 33394748

Citations 4

Authors

Robert M Burkes

Ralph J Panos

Michael T Borchers

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review discusses emerging therapies directed at chronic obstructive pulmonary disease (COPD) endotypes and pathobiological processes that manifest as the disease.

Recent Findings: Specific endotypes have been targeted in COPD. These include eosinophilic inflammation, overproduction of interleukin-17, chronic bronchitis and altered nature of mucous, and chronic infection. Therapies exactly directed at the cause of these endotypes or their resultant clinical findings have been assessed. Although some intermediate outcomes have seemed promising, there have been no findings that shift the paradigm of COPD therapy.

Summary: Basic and clinical scientists continue to define endotypes that may be directly addressed with therapeutics. As of the time of this up-to-date review, there is yet to be an endotype-directed therapy to demonstrate great clinical effect.

Citing Articles

The impact of body mass index on mortality in COPD: an updated dose-response meta-analysis.

Tenda E, Henrina J, Setiadharma A, Felix I, Yulianti M, Pitoyo C Eur Respir Rev. 2024; 33(174).

PMID: 39603663 PMC: 11600125. DOI: 10.1183/16000617.0261-2023.

Associations of Smoking, Cytomegalovirus Serostatus, and Natural Killer Cell Phenotypes in Smokers With and At Risk for COPD.

Burkes R, Bailey E, Hwalek T, Osterburg A, Lach L, Panos R Chronic Obstr Pulm Dis. 2023; 10(3):286-296.

PMID: 37267601 PMC: 10484488. DOI: 10.15326/jcopdf.2022.0382.

Metabolomics Reveals Dysregulated Sphingolipid and Amino Acid Metabolism Associated with Chronic Obstructive Pulmonary Disease.

Kim J, Suresh B, Lim M, Hong S, Kim K, Song H Int J Chron Obstruct Pulmon Dis. 2022; 17:2343-2353.

PMID: 36172036 PMC: 9511892. DOI: 10.2147/COPD.S376714.

Computed Tomography Registration-Derived Regional Ventilation Indices Compared to Global Lung Function Parameters in Patients With COPD.

Cohen J, Shekarnabi M, Destors M, Tamisier R, Bouzon S, Orkisz M Front Physiol. 2022; 13:862186.

PMID: 35721545 PMC: 9202420. DOI: 10.3389/fphys.2022.862186.

References

Petersen H, Vazquez Guillamet R, Meek P, Sood A, Tesfaigzi Y . Early Endotyping: A Chance for Intervention in Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2018; 59(1):13-17. PMC: 6039877. DOI: 10.1165/rcmb.2018-0002PS. View

Dima E, Kyriakoudi A, Kaponi M, Vasileiadis I, Stamou P, Koutsoukou A . The lung microbiome dynamics between stability and exacerbation in chronic obstructive pulmonary disease (COPD): Current perspectives. Respir Med. 2019; 157:1-6. DOI: 10.1016/j.rmed.2019.08.012. View

Xiong J, Tian J, Zhou L, Le Y, Sun Y . Interleukin-17A Deficiency Attenuated Emphysema and Bone Loss in Mice Exposed to Cigarette Smoke. Int J Chron Obstruct Pulmon Dis. 2020; 15:301-310. PMC: 7020917. DOI: 10.2147/COPD.S235384. View

Van Rossem I, Vandevoorde J, Hanon S, Deridder S, Vanderhelst E . The stability of blood eosinophils in stable chronic obstructive pulmonary disease: a retrospective study in Belgian primary care. BMC Pulm Med. 2020; 20(1):200. PMC: 7376637. DOI: 10.1186/s12890-020-01234-3. View

Singanayagam A, Glanville N, Cuthbertson L, Bartlett N, Finney L, Turek E . Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci Transl Med. 2019; 11(507). PMC: 7237237. DOI: 10.1126/scitranslmed.aav3879. View

Narendra D, Hanania N . Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1045-1051. PMC: 6529620. DOI: 10.2147/COPD.S155306. View

Miravitlles M, Soler-Cataluna J, Calle M, Molina J, Almagro P, Quintano J . Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014; 50 Suppl 1:1-16. DOI: 10.1016/S0300-2896(14)70070-5. View

Bennett W, Henderson A, Ceppe A, Zeman K, Wu J, Gladman C . Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Res. 2020; 6(3). PMC: 7418818. DOI: 10.1183/23120541.00269-2020. View

Burkes R, Astemborski J, Lambert A, Brown T, Wise R, Kirk G . Plasma cathelicidin and longitudinal lung function in current and former smokers. PLoS One. 2019; 14(2):e0212628. PMC: 6392327. DOI: 10.1371/journal.pone.0212628. View

10.

Singh D, Wedzicha J, Siddiqui S, de la Hoz A, Xue W, Magnussen H . Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020; 21(1):240. PMC: 7499955. DOI: 10.1186/s12931-020-01482-1. View

11.

Pavord I, Chanez P, Criner G, Kerstjens H, Korn S, Lugogo N . Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017; 377(17):1613-1629. DOI: 10.1056/NEJMoa1708208. View

12.

Onishi R, Gaffen S . Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010; 129(3):311-21. PMC: 2826676. DOI: 10.1111/j.1365-2567.2009.03240.x. View

13.

Burkes R, Ceppe A, Couper D, Comellas A, Wells J, Peters S . Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstr Pulm Dis. 2020; 7(4):370-381. PMC: 7883905. DOI: 10.15326/jcopdf.7.4.2020.0142. View

14.

Taylor S, OFarrell H, Simpson J, Yang I, Rogers G . The contribution of respiratory microbiome analysis to a treatable traits model of care. Respirology. 2018; 24(1):19-28. DOI: 10.1111/resp.13411. View

15.

Tang S, Ma T, Zhang H, Zhang J, Zhong X, Tan C . Erythromycin Prevents Elastin Peptide-Induced Emphysema and Modulates CD4T Cell Responses in Mice. Int J Chron Obstruct Pulmon Dis. 2019; 14:2697-2709. PMC: 6890220. DOI: 10.2147/COPD.S222195. View

16.

Criner G, Celli B, Brightling C, Agusti A, Papi A, Singh D . Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019; 381(11):1023-1034. DOI: 10.1056/NEJMoa1905248. View

17.

Weng J, Wang Y, Sun T . Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats. Chin Med J (Engl). 2019; 132(5):569-576. PMC: 6415994. DOI: 10.1097/CM9.0000000000000107. View

18.

OQuinn D, Palmer M, Lee Y, Weaver C . Emergence of the Th17 pathway and its role in host defense. Adv Immunol. 2009; 99:115-63. DOI: 10.1016/S0065-2776(08)00605-6. View

19.

Garner J, Shaipanich T, Hartman J, Orton C, Caneja C, Klooster K . A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD. Eur Respir J. 2020; 56(6). PMC: 7744607. DOI: 10.1183/13993003.00556-2020. View

20.

Brandsma C, van den Berge M, Hackett T, Brusselle G, Timens W . Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J Pathol. 2019; 250(5):624-635. PMC: 7216938. DOI: 10.1002/path.5364. View